AstraZeneca’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholders in TeneoBio, who could stand to see even more upside in the years ahead, says Associate Editor Paul Bonanos on the latest edition of the BioCentury This Week podcast. Bonanos and the BioCentury editors also discuss how TeneoTwo investor Lightspeed Venture Partners has deepened its commitment ([ Ссылка ]) to life sciences investing; Arch Venture Partners’ plans ([ Ссылка ]) to deploy its new $3 billion venture fund; and the latest translational highlights from BioCentury’s Distillery ([ Ссылка ]) and Translational in Brief ([ Ссылка ]) sections. Plus: A preview of BioCentury's fall conference.
